ArticleStroke2015
Biomarkers and mortality after transient ischemic attack and minor ischemic stroke: population-based study.
Article in Stroke, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Pooled it
- Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis.Journal of translational medicine · 2022Pooled it
- Education Level and Long-term Mortality, Recurrent Stroke, and Cardiovascular Events in Patients With Ischemic Stroke.Journal of the American Heart Association · 2020Trial
- Article
- Differential Diagnostic Value of Neutrophil Gelatinase-Associated Lipocalin and Cystatin C in Ischemic Stroke Patients with or without Chronic Kidney Disease.Journal of inflammation research · 2026Article
- L-FABP as a Potential Biomolecular Marker of Liver Graft Injury.Journal of clinical medicine · 2025Article
- H-FABP as a Biomarker in Transient Ischemic Attack.Journal of cardiovascular translational research · 2025Article
- Releasing Dynamic of Serum ST2 and Calprotectin in Patients with Acute Ischemic Stroke.Diagnostics (Basel, Switzerland) · 2024Article
- A novel biomarker panel index improves risk stratification after ischemic stroke.European stroke journal · 2022Article
- Elevated Plasma von Willebrand Factor Levels Are Associated With Subsequent Ischemic Stroke in Persons With Treated HIV Infection.Open forum infectious diseases · 2021Article
- Associations of blood biomarkers with glomerular filtration rate in patients with TIA and stroke: population-based study.Stroke and vascular neurology · 2021Article
- The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.Scientific reports · 2021Article
- N-Terminal pro-B-type natriuretic peptide and stroke risk across a spectrum of cerebrovascular disease: The REasons for Geographic and Racial Differences in Stroke cohort.Research and practice in thrombosis and haemostasis · 2020Article
- Biomarkers levels and brachial and central blood pressure during the subacute phase of lacunar stroke and other ischemic stroke subtypes.Journal of human hypertension · 2020Article
- Biochemical Parameters in Cognitive Functions.Neuropsychiatric disease and treatment · 2020Review
- Identification of novel blood biomarker panels to detect ischemic stroke in patients and their responsiveness to therapeutic intervention.Brain research · 2018Article
- Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array.Acta pharmacologica Sinica · 2018Article
- Plasma Exosomal miRNA-122-5p and miR-300-3p as Potential Markers for Transient Ischaemic Attack in Rats.Frontiers in aging neuroscience · 2018Article
- Heads and Tails of Natriuretic Peptides: Neuroprotective Role of Brain Natriuretic Peptide.Journal of the American Heart Association · 2017Article
- Association Between Serum Tumor Necrosis Factor Receptor 1 and Trajectories of Functional Status: The Northern Manhattan Study.American journal of epidemiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
background and purposePremature death after transient ischemic attack or stroke is more often because of heart disease or cancer than stroke. Previous studies found blood biomarkers not usefully predictive of nonfatal stroke but possibly of all-cause death. This association might be explained by potentially treatable occult cardiac disease or cancer. We therefore aimed to validate the association of a panel of biomarkers with all-cause death, particularly cardiac death and cancer death, despite the absence of associations with risk of nonfatal vascular events.
methodsFifteen biomarkers were measured in 929 consecutive patients in a population-based study (Oxford Vascular Study), recruited from 2002 and followed up to 2013. Associations were determined by Cox regression. Model discrimination was assessed by c-statistic and the integrated discrimination improvement.
resultsDuring 5560 patient-years of follow-up, none of the biomarkers predicted risk of nonfatal vascular events. However, soluble tumor necrosis factor α receptor-1, von Willebrand factor, heart-type fatty-acid-binding protein, and N-terminal pro-B-type natriuretic peptide were independently predictive of all-cause death (n=361; adjusted hazard ratio per SD, 95% confidence interval: heart-type fatty-acid-binding protein: 1.31, 1.12-1.56, P=0.002; N-terminal pro-B-type natriuretic peptide: 1.34, 1.11-1.62, P=0.002; soluble tumor necrosis factor α receptor-1: 1.45, 1.26-1.66, P=0.02; von Willebrand factor: 1.19, 1.04-1.36, P=0.01). The independent contribution of the four biomarkers taken together added prognostic information and improved model discrimination (integrated discrimination improvement=0.028, P=0.0001). N-terminal pro-B-type natriuretic peptide was most predictive of vascular death (adjusted hazard ratio=1.80, 95% confidence interval, 1.34-2.41, P<0.0001), whereas heart-type fatty-acid-binding protein predicted cancer deaths (1.64, 1.26-2.12, P=0.0002). Associations were strongest in patients without known prior cardiac disease or cancer.
conclusionsSeveral biomarkers predicted death of any cause after transient ischemic attack and minor stroke. N-terminal pro-B-type natriuretic peptide and heart-type fatty-acid-binding protein might improve patient selection for additional screening for occult cardiac disease or cancer, respectively. However, our results require validation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.